PreprintCited by 37Mass Spectrometry Techniques and ApplicationsGlycosylation and Glycoproteins ResearchAdvanced Proteomics Techniques and Applications

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Exposing the molecular heterogeneity of glycosylated biotherapeutics

Open access

Preprint — published as 10.1038/s41467-024-47693-8 · Paper page

Abstract

Glycosylated biotherapeutics are an emerging class of drugs with high molecular heterogeneity, which can affect their safety and efficacy. Characterizing this heterogeneity is crucial for drug development and quality assessment, but existing methods are limited in their ability to analyze intact glycoproteins. Here, we present a new approach to glycoform fingerprinting that uses proton-transfer charge-reduction with gas-phase fractionation to analyze intact glycoproteins by mass spectrometry. The method provides a detailed landscape of the intact molecular weights present in biotherapeutic protein preparations in a single experiment and offers insights into glycoform composition when coupled with a suitable bioinformatic strategy. We tested the approach on various biotherapeutic molecules, including Fc-fusion, VHH-fusion, and peptide-bound MHC class II complexes to demonstrate efficacy in measuring the proteoform-level diversity of biotherapeutics. Notably, we inferred the glycoform distribution for hundreds of molecular weights for the eight-times glycosylated fusion drug IL22-Fc, enabling correlations between glycoform sub-populations and the drug’s pharmacological properties. Our method is broadly applicable and provides a powerful tool to assess the molecular heterogeneity of emerging biotherapeutics.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.21203/rs.3.rs-2928767/v1

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 58

  1. Rathore, A. S. & Winkle, H. Quality by design for biopharmaceuticals. Nat Biotechnol 27, 26–34 (2009). · DOI
  2. Walsh, G. Biopharmaceutical benchmarks 2018. Nat Biotechnol 36, 1136–1145 (2018). · DOI · Paper page
  3. Zhang, P. et al. Challenges of glycosylation analysis and control: an integrated approach to producing optimal and consistent therapeutic drugs. Drug Discov Today 21, 740–765 (2016). · DOI
  4. Yehuda, S. & Padler-Karavani, V. Glycosylated Biotherapeutics: Immunological Effects of N-Glycolylneuraminic Acid. Front Immunol 11, 21 (2020). · DOI · Paper page
  5. Silsirivanit, A. Chapter Five Glycosylation markers in cancer. Adv Clin Chem 89, 189–213 (2019). · DOI
  6. Aebi, M., Bernasconi, R., Clerc, S. & Molinari, M. N-glycan structures: recognition and processing in the ER. Trends Biochem Sci 35, 74–82 (2010). · DOI
  7. Gabius, H.-J. The sugar code: Why glycans are so important. Biosystems 164, 102–111 (2018). · DOI
  8. Elliott, S. et al. Enhancement of therapeutic protein in vivo activities through glycoengineering. Nat Biotechnol 21, 414–421 (2003). · DOI
  9. Lowe, J. B. & Marth, J. D. Essentials of Glycobiology. in Chap. 16, Structures Common to Different Types of Glycans. (eds. A, V., R, C. & J, E.) (Cold Spring Harbor Laboratory Press, 1999).
  10. Mariño, K., Bones, J., Kattla, J. J. & Rudd, P. M. A systematic approach to protein glycosylation analysis: a path through the maze. Nat Chem Biol 6, 713–723 (2010). · DOI
  11. Rathore, D. et al. The role of mass spectrometry in the characterization of biologic protein products. Expert Rev Proteomic 15, 431–449 (2018). · DOI
  12. Rogstad, S. et al. A Retrospective Evaluation of the Use of Mass Spectrometry in FDA Biologics License Applications. J Am Soc Mass Spectr 28, 786–794 (2017). · DOI
  13. Xiao, H., Sun, F., Suttapitugsakul, S. & Wu, R. Global and site-specific analysis of protein glycosylation in complex biological systems with Mass Spectrometry. Mass Spectrom. Rev. 38, 356–379 (2019). · DOI
  14. Shen, J. et al. StrucGP: de novo structural sequencing of site-specific N-glycan on glycoproteins using a modularization strategy. Nat Methods 18, 921–929 (2021). · DOI
  15. Geyer, H. & Geyer, R. Strategies for analysis of glycoprotein glycosylation. Biochimica Et Biophysica Acta Bba - Proteins Proteom 1764, 1853–1869 (2006). · DOI
  16. Wang, T. et al. Application of a Quantitative LC–MS Multiattribute Method for Monitoring Site-Specific Glycan Heterogeneity on a Monoclonal Antibody Containing Two NLinked Glycosylation Sites. Anal Chem 89, 3562–3567 (2017). · DOI
  17. Sun, S. et al. Comprehensive analysis of protein glycosylation by solid-phase extraction of N-linked glycans and glycosite-containing peptides. Nat Biotechnol 34, 84–88 (2016). · DOI
  18. Yang, Y. et al. Hybrid mass spectrometry approaches in glycoprotein analysis and their usage in scoring biosimilarity. Nat Commun 7, 13397 (2016). · DOI · Paper page
  19. Wohlschlager, T. et al. Native mass spectrometry combined with enzymatic dissection unravels glycoform heterogeneity of biopharmaceuticals. Nat Commun 9, 1713 (2018). · DOI
  20. Solá, R. J. & Griebenow, K. Glycosylation of Therapeutic Proteins. Biodrugs 24, 9–21 (2010). · DOI
  21. Stephenson, J. L., Berkel, G. J. V. & McLuckey, S. A. Ion-ion proton transfer reactions of bio-ions involving noncovalent interactions: Holomyoglobin. J Am Soc Mass Spectr 8, 637–644 (1997). · DOI · Paper page
  22. Stephenson, J. L. & McLuckey, S. A. Ion/Ion Proton Transfer Reactions for Protein Mixture Analysis. Anal Chem 68, 4026–4032 (1996). · DOI · Paper page
  23. Anderson, L. C. et al. Protein derivatization and sequential ion/ion reactions to enhance sequence coverage produced by electron transfer dissociation mass spectrometry. Int J Mass Spectrom 377, 617–624 (2015). · DOI · Paper page
  24. Coon, J. J. et al. Protein identification using sequential ion/ion reactions and tandem mass spectrometry. Proc National Acad Sci 102, 9463–9468 (2005). · DOI · Paper page
  25. Huguet, R. et al. Proton Transfer Charge Reduction Enables High-Throughput Top-Down Analysis of Large Proteoforms. Anal Chem 91, 15732–15739 (2019). · DOI · Paper page
  26. Belov, M. E. et al. From Protein Complexes to Subunit Backbone Fragments: A Multi-stage Approach to Native Mass Spectrometry. Anal Chem 85, 11163–11173 (2013). · DOI · Paper page
  27. Kafader, J. O. et al. Native vs Denatured: An in Depth Investigation of Charge State and Isotope Distributions. J Am Soc Mass Spectr 31, 574–581 (2020). · DOI · Paper page
  28. Cai, X. et al. PulseDIA: Data-Independent Acquisition Mass Spectrometry Using Multi-Injection Pulsed Gas-Phase Fractionation. J Proteome Res 20, 279–288 (2021). · DOI
  29. Smith, L. M. et al. Proteoform: a single term describing protein complexity. Nat Methods 10, 186–187 (2013). · DOI · Paper page
  30. Leney, A. C. & Heck, A. J. R. Native Mass Spectrometry: What is in the Name? J Am Soc Mass Spectr 28, 5–13 (2017). · DOI · Paper page
  31. Čaval, T., Tian, W., Yang, Z., Clausen, H. & Heck, A. J. R. Direct quality control of glycoengineered erythropoietin variants. Nat Commun 9, 3342 (2018). · DOI
  32. Marty, M. T. et al. Bayesian Deconvolution of Mass and Ion Mobility Spectra: From Binary Interactions to Polydisperse Ensembles. Anal Chem 87, 4370–4376 (2015). · DOI · Paper page
  33. Muthu, M. et al. Insights into Bioinformatic Applications for Glycosylation: Instigating an Awakening towards Applying Glycoinformatic Resources for Cancer Diagnosis and Therapy. Int J Mol Sci 21, 9336 (2020). · DOI
  34. Rojas-Macias, M. A. et al. Towards a standardized bioinformatics infrastructure for N- and O-glycomics. Nat Commun 10, 3275 (2019). · DOI
  35. Rogstad, S. et al. Multi-Attribute Method for Quality Control of Therapeutic Proteins. Anal Chem 91, 14170–14177 (2019). · DOI · Paper page
  36. Rogers, R. S. et al. Development of a quantitative mass spectrometry multi-attribute method for characterization, quality control testing and disposition of biologics. Mabs 7, 881–890 (2015). · DOI · Paper page
  37. Rademacher, C. & Paulson, J. C. Glycan Fingerprints: Calculating Diversity in Glycan Libraries. Acs Chem Biol 7, 829–834 (2012). · DOI
  38. FDA. Guidance for Industry: Q11 Development and Manufacture of Drug Substances. Preprint at https://www.fda.gov/files/drugs/published/Q11-Development-and-Manufacture-of-Drug-Substances.pdf (2012).
  39. Gabius, H. et al. What is the Sugar Code? Chembiochem 23, e202100327 (2022).
  40. Atwell, S., Ridgway, J. B. B., Wells, J. A. & Carter, P. Stable heterodimers from remodeling the domain interface of a homodimer using a phage display library11Edited by P.E.Wright. J Mol Biol 270, 26–35 (1997). · DOI
  41. Bannas, P., Hambach, J. & Koch-Nolte, F. Nanobodies and Nanobody-Based Human Heavy Chain Antibodies As Antitumor Therapeutics. Front Immunol 8, 1603 (2017). · DOI · Paper page
  42. Yang, Y., Barendregt, A., Kamerling, J. P. & Heck, A. J. R. Analyzing Protein Micro-Heterogeneity in Chicken Ovalbumin by High-Resolution Native Mass Spectrometry Exposes Qualitatively and Semi-Quantitatively 59 Proteoforms. Anal Chem 85, 12037–12045 (2013). · DOI
  43. Schachner, L. F. et al. High-Throughput, Quantitative Analysis of Peptide-Exchanged MHCI Complexes by Native Mass Spectrometry. Anal Chem (2022) doi:10.1021/acs.analchem.2c02423. · DOI
  44. Ott, P. A. et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature 547, 217–221 (2017). · DOI · Paper page
  45. Ryan, S. O. & Cobb, B. A. Roles for major histocompatibility complex glycosylation in immune function. Semin Immunopathol 34, 425–441 (2012). · DOI
  46. Rothenberg, M. E. et al. Randomized Phase I Healthy Volunteer Study of UTTR1147A (IL-22Fc): A Potential Therapy for Epithelial Injury. Clin Pharmacol Ther 105, 177–189 (2019). · DOI
  47. Stefanich, E. G. et al. Pre-clinical and translational pharmacology of a human interleukin-22 IgG fusion protein for potential treatment of infectious or inflammatory diseases. Biochem Pharmacol 152, 224–235 (2018). · DOI
  48. Gao, B. & Xiang, X. Interleukin-22 from bench to bedside: a promising drug for epithelial repair. Cell Mol Immunol 16, 666–667 (2019). · DOI
  49. Berndsen, Z. T. et al. Visualization of the HIV-1 Env glycan shield across scales. Proc National Acad Sci 117, 28014–28025 (2020). · DOI · Paper page
  50. Crocker, P. R., Paulson, J. C. & Varki, A. Siglecs and their roles in the immune system. Nat Rev Immunol 7, 255–266 (2007). · DOI
  51. Kightlinger, W. et al. Design of glycosylation sites by rapid synthesis and analysis of glycosyltransferases. Nat Chem Biol 14, 627–635 (2018). · DOI
  52. Meuris, L. et al. GlycoDelete engineering of mammalian cells simplifies N-glycosylation of recombinant proteins. Nat Biotechnol 32, 485–489 (2014). · DOI · Paper page
  53. Hershewe, J. M. et al. Improving cell-free glycoprotein synthesis by characterizing and enriching native membrane vesicles. Nat Commun 12, 2363 (2021). · DOI
  54. Jaroentomeechai, T. et al. Single-pot glycoprotein biosynthesis using a cell-free transcription-translation system enriched with glycosylation machinery. Nat Commun 9, 2686 (2018). · DOI
  55. Schachner, L. F. et al. Decoding the protein composition of whole nucleosomes with Nuc-MS. Nat Methods 18, 303–308 (2021). · DOI
  56. Ruthenburg, A. J. et al. Recognition of a Mononucleosomal Histone Modification Pattern by BPTF via Multivalent Interactions. Cell 145, 692–706 (2011). · DOI
  57. Casalino, L. et al. Beyond Shielding: The Roles of Glycans in the SARS-CoV-2 Spike Protein. Acs Central Sci 6, 1722–1734 (2020). · DOI
  58. Sperinde, G. et al. Challenges with development of a pharmacokinetics assay to measure a variably glycosylated fusion protein. Bioanalysis 14, 7–18 (2021). · DOI

Metadata

Authors
Schachner, L., Mullen, C., Phung, W., Hinkle, J., Beardsley, M. I., Bentley, T., Day, P., Tsai, C., Sukumaran, S., Baginski, T., DiCara, D., Agard, N., Masureel, M., Gober, J., ElSohly, A., Syka, J., Huguet, R., Marty, M., & Sandoval, W.
Affiliations
  • Genentech (US)
  • Thermo Fisher Scientific (United States) (US)
  • University of Arizona (US)
Corresponding author
Sandoval, Wendy
Venue
Nature Communications
Published
2023-05-25
Volume
15
Issue
1
Pages
3259-3259
ISSN
2041-1723 (ISSN-L)
OpenAlex
W4394845195
Cited by
37
References
1
Citations by year
2026: 19 · 2025: 12 · 2024: 6
FWCI
4.59
Type
journal article
Language
en
Open access
Locations
  • Nature Communications (publishedVersion, cc-by)
  • bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by-nc-nd)
  • Research Square (acceptedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Science Foundation (1845230)
  • Genentech
  • Division of Chemistry (CHE-1845230)
Topics
  • Physical Sciences › Chemistry › Spectroscopy › Mass Spectrometry Techniques and Applications
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Glycosylation and Glycoproteins Research
  • Physical Sciences › Chemistry › Spectroscopy › Advanced Proteomics Techniques and Applications
Keywords
molecular heterogeneity, glycoproteins, gas-phase fractionation, proteoforms, Fc fusion protein, glycan composition
MeSH terms
Glycoproteins, Glycosylation, Polysaccharides, Mass Spectrometry

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review